secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theriva Biologics, Inc. (TOVX)
CIK:        0000894158
Form:       8-K
Filed at:   2026-06-11T12:10:25+00:00
Accession:  0001104659-26-072633
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Theriva Biologics announces VCN-01 Phase 1 HNSCC data showing median OS up to 17.3 months
--------------------------------------------------------------------------------

- Median OS 10.3-17.3 months across three arms in heavily pre-treated, immunotherapy-refractory HNSCC patients.
- Median PFS 1.6-3.7 months; best PFS (3.7 mo) in sequential low-dose VCN-01 arm (Arm II LD).
- Biomarker data confirms VCN-01 mechanism: increased PH20, viral replication, CD8+ T cell infiltration, PD-L1 upregulation.
- Results published online in Clinical Cancer Research; trial NCT03799744 enrolled 20 patients.
- Data suggest VCN-01 can resensitize refractory tumors to checkpoint inhibitor durvalumab.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/894158/000110465926072633/0001104659-26-072633-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/894158/000110465926072633/tm2617564d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-072633

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer